- Home
- LSTA vs RLYB Comparison
LSTA vs RLYB Comparison
Compare LSTA & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- RLYB
- Stock Information
- Founded
- LSTA 1980
- RLYB 2018
- Country
- LSTA United States
- RLYB United States
- Employees
- LSTA N/A
- RLYB N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- RLYB Health Care
- Exchange
- LSTA Nasdaq
- RLYB Nasdaq
- Market Cap
- LSTA 22.3M
- RLYB 24.1M
- IPO Year
- LSTA N/A
- RLYB 2021
- Fundamental
- Price
- LSTA $2.17
- RLYB $0.61
- Analyst Decision
- LSTA Strong Buy
- RLYB Hold
- Analyst Count
- LSTA 2
- RLYB 2
- Target Price
- LSTA $23.50
- RLYB N/A
- AVG Volume (30 Days)
- LSTA 25.5K
- RLYB 442.0K
- Earning Date
- LSTA 08-07-2025
- RLYB 11-06-2025
- Dividend Yield
- LSTA N/A
- RLYB N/A
- EPS Growth
- LSTA N/A
- RLYB N/A
- EPS
- LSTA N/A
- RLYB N/A
- Revenue
- LSTA $1,070,000.00
- RLYB $761,000.00
- Revenue This Year
- LSTA N/A
- RLYB N/A
- Revenue Next Year
- LSTA N/A
- RLYB N/A
- P/E Ratio
- LSTA N/A
- RLYB N/A
- Revenue Growth
- LSTA N/A
- RLYB 154.51
- 52 Week Low
- LSTA $1.87
- RLYB $0.22
- 52 Week High
- LSTA $4.20
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- LSTA 37.46
- RLYB 59.14
- Support Level
- LSTA $2.55
- RLYB $0.49
- Resistance Level
- LSTA $2.63
- RLYB $0.61
- Average True Range (ATR)
- LSTA 0.17
- RLYB 0.05
- MACD
- LSTA -0.04
- RLYB -0.00
- Stochastic Oscillator
- LSTA 17.86
- RLYB 74.13
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.